X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3071) 3071
Book Review (494) 494
Publication (198) 198
Newsletter (150) 150
Book Chapter (19) 19
Newspaper Article (12) 12
Book / eBook (9) 9
Conference Proceeding (9) 9
Magazine Article (7) 7
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2731) 2731
index medicus (2669) 2669
burkitt lymphoma - drug therapy (1511) 1511
male (1278) 1278
female (1067) 1067
oncology (919) 919
child (770) 770
burkitt lymphoma - pathology (761) 761
adult (683) 683
burkitt's lymphoma (672) 672
hematology (650) 650
antineoplastic combined chemotherapy protocols - therapeutic use (635) 635
cancer (627) 627
adolescent (609) 609
child, preschool (521) 521
lymphomas (487) 487
chemotherapy (481) 481
middle aged (431) 431
animals (428) 428
lymphoma (384) 384
burkitt lymphoma (363) 363
abridged index medicus (353) 353
treatment outcome (335) 335
apoptosis (333) 333
burkitt lymphoma - diagnosis (327) 327
cell line, tumor (312) 312
mice (309) 309
children (306) 306
burkitt lymphoma - genetics (296) 296
prognosis (288) 288
burkitts-lymphoma (281) 281
leukemia (275) 275
non-hodgkins-lymphoma (270) 270
pediatrics (257) 257
research (257) 257
burkitt lymphoma - complications (250) 250
cyclophosphamide - therapeutic use (250) 250
antineoplastic agents - therapeutic use (245) 245
burkitt lymphoma - metabolism (243) 243
cyclophosphamide - administration & dosage (240) 240
aged (237) 237
rituximab (232) 232
burkitt lymphoma - immunology (230) 230
methotrexate - administration & dosage (223) 223
therapy (221) 221
care and treatment (219) 219
burkitt-lymphoma (214) 214
acute lymphoblastic-leukemia (212) 212
b-cell lymphoma (210) 210
vincristine - administration & dosage (208) 208
burkitt lymphoma - therapy (203) 203
apoptosis - drug effects (202) 202
infant (202) 202
health aspects (195) 195
tumor cells, cultured (188) 188
burkitt lymphoma - mortality (180) 180
expression (179) 179
hemic and lymphatic diseases (177) 177
remission induction (173) 173
epstein-barr virus (165) 165
antineoplastic agents - pharmacology (164) 164
drug therapy (160) 160
tumors (158) 158
neoplasm staging (157) 157
immunology (155) 155
cytarabine - administration & dosage (151) 151
doxorubicin - administration & dosage (151) 151
risk factors (150) 150
retrospective studies (149) 149
antineoplastic combined chemotherapy protocols - adverse effects (146) 146
vincristine - therapeutic use (145) 145
lymphoma, non-hodgkin - drug therapy (143) 143
time factors (142) 142
follow-up studies (140) 140
non-hodgkin's lymphomas (138) 138
antineoplastic combined chemotherapy protocols - administration & dosage (137) 137
burkitt lymphoma - virology (135) 135
diagnosis (134) 134
epstein-barr-virus (134) 134
survival (134) 134
proteins (133) 133
methotrexate - therapeutic use (132) 132
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (132) 132
survival rate (130) 130
combined modality therapy (129) 129
flow cytometry (129) 129
biochemistry & molecular biology (127) 127
diagnosis, differential (127) 127
cell biology (124) 124
cell line (124) 124
analysis (123) 123
c-myc (123) 123
dose-response relationship, drug (123) 123
genetic aspects (123) 123
burkitt lymphoma - etiology (122) 122
prednisone - administration & dosage (122) 122
childhood (120) 120
gene expression (118) 118
lymphoma, large b-cell, diffuse - drug therapy (118) 118
lymphoma, b-cell - drug therapy (116) 116
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2999) 2999
French (67) 67
German (51) 51
Spanish (40) 40
Japanese (29) 29
Chinese (27) 27
Russian (21) 21
Polish (7) 7
Italian (6) 6
Danish (3) 3
Hungarian (3) 3
Dutch (2) 2
Norwegian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Hebrew (1) 1
Portuguese (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 1, pp. 44 - 50
Purpose Aurora A kinase (AAK) is overexpressed in aggressive lymphomas and can correlate with more histologically aggressive forms of disease. We therefore... 
SURVIVAL | IN-VITRO | ADVANCED SOLID TUMORS | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | SYNTHETIC LETHAL | MYC | VINCRISTINE | MLN8237 | LEUKEMIA CELLS | NF-KAPPA-B | Burkitt Lymphoma - enzymology | Recurrence | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Lymphoma, T-Cell - enzymology | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Azepines - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Pyrimidines - administration & dosage | Lymphoma, Large B-Cell, Diffuse - enzymology | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Azepines - therapeutic use | Protein Kinase Inhibitors - administration & dosage | Lymphoma, T-Cell - drug therapy | Lymphoma, Mantle-Cell - enzymology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Lymphoma, Follicular - enzymology | Aged | Azepines - pharmacokinetics | Azepines - administration & dosage | Index Medicus | Hema13 | ORIGINAL REPORTS
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4212 - 4223
Purpose: Patients with B-cell lymphomas often relapse after frontline therapy, and novel therapies are urgently needed to provide long-term remission. We... 
ONCOLOGY | RITUXIMAB | BONE-MARROW | INVOLVEMENT | IBRUTINIB | RESISTANCE | NON-HODGKIN-LYMPHOMA | CANCER | CHEMOTHERAPY | TRANSPLANTATION | FEATURES | Lymphoma, Follicular - drug therapy | Humans | Lymphoma, Mantle-Cell - pathology | Protein Kinase Inhibitors - adverse effects | Burkitt Lymphoma - pathology | Protein-Tyrosine Kinases - genetics | Lymphoma, Follicular - genetics | Burkitt Lymphoma - genetics | Lymphoma, B-Cell, Marginal Zone - pathology | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, Mantle-Cell - genetics | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Precision Medicine | Pyrazoles - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Pyrimidines - administration & dosage | Lymphoma, Mantle-Cell - drug therapy | Drug Discovery | Lymphoma, B-Cell, Marginal Zone - genetics | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Animals | Signal Transduction - drug effects | Lymphoma, B-Cell, Marginal Zone - drug therapy | Lymphoma, Large B-Cell, Diffuse - classification | Pyrimidines - adverse effects | Mice | Lymphoma, Large B-Cell, Diffuse - genetics | Cell culture | Therapy | Animal models | Kinases | Inactivation | Signal transduction | Biological effects | Peripheral blood | Xenografts | Remission | Protein-tyrosine kinase | Tyrosine | Deactivation | Tumor cells | Patients | Lymphoma | 1-Phosphatidylinositol 3-kinase | Burkitt's lymphoma | Signaling | Inhibitors | Lymphocytes B | Experimental design | Mantle cell lymphoma | Lymphomas | Mutation | Tumors | Cancer | B-cell lymphoma | Index Medicus | patient-derived xenograft | personalized therapy
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2015, Volume 171, Issue 5, pp. 763 - 775
Obinutuzumab is a novel glycoengineered Type‐ II CD 20 monoclonal antibody. CD 20 is expressed in approximately 100% of children and adolescents with Burkitt... 
ALL | pre‐B | BL | rituximab‐sensitive | rituximab‐resistant | obinutuzumab | rituximab | Rituximab | Obinutuzumab | Pre-B-ALL | Rituximab-sensitive BL | Rituximab-resistant BL | pre-B-ALL | NATURAL-KILLER-CELLS | ONCOLOGY GROUP-REPORT | rituximab-sensitive BL | rituximab-resistant ill | PHASE I/II | CHEMOTHERAPY PLUS RITUXIMAB | CHILDREN | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | HEMATOLOGY | Neoplasm Transplantation | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Rituximab - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Caspases - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Survival Analysis | Cell Line, Tumor | Caspases - drug effects | Lysosomal-Associated Membrane Protein 1 - metabolism | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Interferon-gamma - biosynthesis | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | Cell death | Patient outcomes | Monoclonal antibodies | Biochemistry | Comparative analysis | Antineoplastic agents | Burkitt's lymphoma | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 20, pp. 1915 - 1925
Toxic high-dose chemotherapy may not be necessary to cure Burkitt's lymphoma in adults and patients with immunodeficiency. An infusion-based chemotherapy... 
CHEMOTHERAPY REGIMEN | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | CODOX-M/IVAC | EVENT-FREE SURVIVAL | RITUXIMAB | DOXORUBICIN | NON-HODGKINS-LYMPHOMA | DOSE-ADJUSTED EPOCH | ANTIRETROVIRAL THERAPY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | HIV Seropositivity - complications | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Burkitt Lymphoma - complications | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Adolescent | Vincristine - adverse effects | Aged | Immunocompromised Host | Doxorubicin - adverse effects | Pediatrics | Laboratories | Leukemia | Nervous system | Cancer therapies | Doxorubicin | Human immunodeficiency virus--HIV | Children | Drug dosages | Neurological disorders | Neutropenia | Risk groups | Cyclin-dependent kinases | Neutrophils | Fluid | Etoposide | Rituximab | Prednisone | Vincristine | Lymphoma | Patients | Fever | Burkitt's lymphoma | Studies | Cyclophosphamide | Chemotherapy | Lymphocytes B | Lysis | Lymphomas | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 559 - 564
To the authors' knowledge, the current study is the first large comparative analysis of double‐hit lymphomas by patterns of oncogene rearrangement. Patterns of... 
BCL6 (B‐cell lymphoma 6) | non‐Hodgkin lymphoma | gene rearrangement | BCL2 (B‐cell lymphoma 2) | MYC | BCL6 (B-cell lymphoma 6) | non-Hodgkin lymphoma | BCL2 (B-cell lymphoma 2) | RITUXIMAB PLUS CYCLOPHOSPHAMIDE | TRANSLOCATIONS | IN-VIVO EFFICACY | DOXORUBICIN | B-CELL LYMPHOMA | PREDNISONE | BCL6 | ONCOLOGY | VINCRISTINE | EXPRESSION | Doxorubicin - therapeutic use | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Bone Marrow Neoplasms - genetics | Lymphoma, B-Cell - genetics | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Burkitt Lymphoma - pathology | Burkitt Lymphoma - genetics | Female | Burkitt Lymphoma - drug therapy | Databases, Factual | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - drug therapy | Ifosfamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Central Nervous System Neoplasms - genetics | Etoposide - therapeutic use | Survival Rate | Germinal Center - pathology | Lymphoma, Non-Hodgkin - genetics | DNA-Binding Proteins - genetics | Genes, bcl-2 - genetics | Rituximab - administration & dosage | Central Nervous System Neoplasms - pathology | Dexamethasone - therapeutic use | Bone Marrow Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gene Rearrangement | Genes, myc - genetics | Lymphoma, B-Cell - pathology | Vincristine - therapeutic use | Bone Marrow Neoplasms - drug therapy | Central Nervous System Neoplasms - drug therapy | Lymphoma, Large B-Cell, Diffuse - genetics | Prednisone - therapeutic use | Cohort Studies | Proto-Oncogene Proteins c-bcl-6 | Care and treatment | Chemotherapy | Usage | Non-Hodgkin's lymphomas | Diagnosis | Research | Oncogenes | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 11, pp. 2273 - 2279
Journal Article
Nature, ISSN 0028-0836, 10/2012, Volume 490, Issue 7418, pp. 116 - 120
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 26, pp. 3870 - 3879
Journal Article
Journal Article
NATURE IMMUNOLOGY, ISSN 1529-2908, 08/2017, Volume 18, Issue 8, pp. 889 - 889
Journal Article
Cancer, ISSN 0008-543X, 04/2006, Volume 106, Issue 7, pp. 1569 - 1580
BACKGROUND. Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or... 
chemoimmunotherapy | hyper‐CVAD | acute lymphoblastic leukemia | B‐ALL | rituximab | adult Burkitt lymphoma | Adult Burkitt lymphoma | Rituximab | B-ALL | Acute lymphoblastic leukemia | Hyper-CVAD | Chemoimmunotherapy | SURVIVAL | INDUCED APOPTOSIS | CYCLOPHOSPHAMIDE | STAGE | CHOP CHEMOTHERAPY | CHILDREN | ONCOLOGY | HIGH-DOSE THERAPY | NON-HODGKINS-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | STEM-CELL TRANSPLANTATION | hyper-CVAD | Cyclophosphamide - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Survival Analysis | Vincristine - administration & dosage | Female | Infusions, Intravenous | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Care and treatment | Chemotherapy | Cyclophosphamide | Dexamethasone | Patient outcomes | Research | Acute lymphocytic leukemia | Vincristine | Doxorubicin | Burkitt's lymphoma | Cancer | Index Medicus | Abridged Index Medicus
Journal Article